Dietary Supplements and Nutraceuticals in the Management of Andrologic Disorders

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 2, 2007, Pages 533-552

  Tamler, Ronald ^a   Mechanick, Jeffrey I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AFLATOXIN; ANTIOXIDANT; ARGININE; ASPIDOSPERMINE; CHONDROITIN; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUCOSAMINE; GLYCYRRHIZA EXTRACT; LEVACECARNINE; LYCOPENE; METHIONINE; NUTRACEUTICAL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; POLICOSANOL; PRASTERONE; PROPIONYLCARNITINE; REHMANNIA GLUTINOSA EXTRACT; RETINOL; SABAL EXTRACT; SELENIUM; SILDENAFIL; TADALAFIL; TESTOSTERONE UNDECANOATE; TRAZODONE; UNINDEXED DRUG; URTICA DIOICA EXTRACT; YOHIMBINE;

ANXIETY DISORDER; BLEEDING; DIET SUPPLEMENTATION; ERECTILE DYSFUNCTION; GINKGO BILOBA; GINSENG; HEART PALPITATION; HUMAN; HYPERTENSION; LIBIDO DISORDER; MALE GENITAL SYSTEM DISEASE; MOULD; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SABAL; SEIZURE; SIDE EFFECT; TREMOR; VASOCONSTRICTION; YEAST;

ANTIOXIDANTS; ARGININE; CARNITINE; DEHYDROEPIANDROSTERONE; DIET; DIETARY SUPPLEMENTS; GINKGO BILOBA; HUMANS; IMPOTENCE; LIBIDO; MALE; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC DISEASES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; YOHIMBINE;

EID: 34249313343     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.03.005     Document Type: Review

References (209)

1. Shah J. Erectile dysfunction through the ages. BJU Int 90 4 (2002) 433-441
2. Eisenberg D.M., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280 18 (1998) 1569-1575
3. Scally M.C., and Hodge A. Health supplement regulations and consumer protection rights. South Med J 93 12 (2000) 1230-1232
4. Scally M.C., Hodge A., and Street C. Prescription for change: health supplement regulations and protecting the public interest. J Natl Med Assoc 93 6 (2001) 230-232
5. Zeisel S.H. Regulation of "nutraceuticals.". Science 285 5435 (1999) 1853-1855
6. Gunther S., et al. Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104 1 (2004) 27-34
7. Barqawi A., et al. Herbal and vitamin supplement use in a prostate cancer screening population. Urology 63 2 (2004) 288-292
8. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 9 5 (2003) 417-470
9. Betz J.M., White K.D., and der Marderosian A.H. Gas chromatographic determination of yohimbine in commercial yohimbe products. J AOAC Int 78 5 (1995) 1189-1194
10. Parasrampuria J., Schwartz K., and Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA 280 18 (1998) 1565
11. Chua R., et al. Quality, labeling accuracy, and cost comparison of purified soy isoflavonoid products. J Altern Complement Med 10 6 (2004) 1053-1060
12. Harkey M.R., et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 73 6 (2001) 1101-1106
13. Arlt V.M., Schmeiser H.H., and Pfeifer G.P. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22 1 (2001) 133-140
14. Gratz S.R., Gamble B.M., and Flurer R.A. Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices. Rapid Commun Mass Spectrom 20 15 (2006) 2317-2327
15. Fleshner N., et al. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. J Urol 174 2 (2005) 636-641 [discussion: 641];[quiz: 801]
16. Centers R, et al. FDA cracks down on illegal sex drugs.
17. D'Ovidio K., et al. Aflatoxins in ginseng roots. Food Addit Contam 23 2 (2006) 174-180
18. Trucksess M., et al. Determination of aflatoxins and ochratoxin A in ginseng and other botanical roots by immunoaffinity column cleanup and liquid chromatography with fluorescence detection. J AOAC Int 89 3 (2006) 624-630
19. Tournas V.H., Katsoudas E., and Miracco E.J. Moulds, yeasts and aerobic plate counts in ginseng supplements. Int J Food Microbiol 108 2 (2006) 178-181
20. Kudo K., et al. A case of poisoning in a man who drank a nutrition supplement containing methomyl, a carbamate pesticide. Fukuoka Igaku Zasshi 96 7 (2005) 305-310
21. Rogan W.J., et al. Recall of a lead-contaminated vitamin and mineral supplement in a clinical trial. Pharmacoepidemiol Drug Saf 8 5 (1999) 343-350
22. Tseng Y.L., Kuo F.H., and Sun K.H. Quantification and profiling of 19-norandrosterone and 19-noretiocholanolone in human urine after consumption of a nutritional supplement and norsteroids. J Anal Toxicol 29 2 (2005) 124-134
23. Baume N., et al. Research of stimulants and anabolic steroids in dietary supplements. Scand J Med Sci Sports 16 1 (2006) 41-48
24. Morris C.A., and Avorn J. Internet marketing of herbal products. Jama 290 11 (2003) 1505-1509
25. Srinivasan V.S. Challenges and scientific issues in the standardization of botanicals and their preparations. United States Pharmacopeia's dietary supplement verification program-a public health program. Life Sci 78 18 (2006) 2039-2043
26. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270 1 (1993) 83-90
27. Benet A.E., and Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 22 4 (1995) 699-709
28. Johannes C.B., et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163 2 (2000) 460-463
29. Moyad M.A. The placebo effect and randomized trials: analysis of alternative medicine. Urol Clin North Am 29 1 (2002) 135-155 x
30. Moyad M.A., et al. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am 31 2 (2004) 259-273
31. Montorsi F., et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53 5 (1999) 1011-1018
32. Dula E., et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 56 1 (2000) 130-135
33. Thompson I.M., et al. Erectile dysfunction and subsequent cardiovascular disease. Jama 294 23 (2005) 2996-3002
34. Arlt W., et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab 84 6 (1999) 2170-2176
35. Pawlikowski M. Adrenal cortex-the next biological clock?. Neuro Endocrinol Lett 26 3 (2005) 193-195
36. Olech E., and Merrill J.T. DHEA supplementation: the claims in perspective. Cleve Clin J Med 72 11 (2005) 965-966 968, 970-1 passim
37. Basar M.M., et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology 66 3 (2005) 597-601
38. Reiter W.J., et al. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology 55 5 (2000) 755-758
39. Feldman H.A., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151 1 (1994) 54-61
40. Reiter W.J., et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 53 3 (1999) 590-594 [discussion: 594-5]
41. Reiter W.J., et al. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 29 4 (2001) 278-281
42. Genazzani A.R., et al. Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency. Aging Male 7 2 (2004) 133-143
43. Jones J.A., et al. Use of DHEA in a patient with advanced prostate cancer: a case report and review. Urology 50 5 (1997) 784-788
44. Morales A.J., et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78 6 (1994) 1360-1367
45. Araghiniknam M., et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sci 59 11 (1996) PL147-PL157
46. Adimoelja A. Phytochemicals and the breakthrough of traditional herbs in the management of sexual dysfunctions. Int J Androl 23 Suppl 2 (2000) 82-84
47. Horton R., and Tait J.F. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 45 3 (1966) 301-313
48. Brown G.A., et al. Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men. Int J Sport Nutr Exerc Metab 10 3 (2000) 340-359
49. King D.S., et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. Jama 281 21 (1999) 2020-2028
50. Wallace M.B., et al. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc 31 12 (1999) 1788-1792
51. Rasmussen B.B., et al. Androstenedione does not stimulate muscle protein anabolism in young healthy men. J Clin Endocrinol Metab 85 1 (2000) 55-59
52. Leder B.Z., et al. Metabolism of orally administered androstenedione in young men. J Clin Endocrinol Metab 86 8 (2001) 3654-3568
53. Leder B.Z., et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 283 6 (2000) 779-782
54. Brown G.A., et al. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab 85 11 (2000) 4074-4080
55. Brown G.A., et al. Effects of androstenedione-herbal supplementation on serum sex hormone concentrations in 30- to 59-year-old men. Int J Vitam Nutr Res 71 5 (2001) 293-301
56. Siegner Jr. A.W. The Food and Drug Administration's actions on ephedra and androstenedione: understanding their potential impacts on the protections of the Dietary Supplement Health and Education Act. Food Drug Law J 59 4 (2004) 617-628
57. Bahrke M.S., and Yesalis C.E. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol 4 6 (2004) 614-620
58. DesJardins M. Supplement use in the adolescent athlete. Curr Sports Med Rep 1 6 (2002) 369-373
59. Lue T.F., and Lee K.L. Pharmacotherapy for erectile dysfunction. Chin Med J (Engl) 113 4 (2000) 291-298
60. Toda N., Ayajiki K., and Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 106 2 (2005) 233-266
61. Zorgniotti A.W., and Lizza E.F. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. Int J Impot Res 6 1 (1994) 33-35 [discussion: 36]
62. Chen J., et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 83 3 (1999) 269-273
63. Klotz T., et al. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int 63 4 (1999) 220-223
64. Fitzpatrick D.F., Bing B., and Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32 4 (1998) 509-515
65. Stanislavov R., and Nikolova V. Treatment of erectile dysfunction with pycnogenol and L-arginine. J Sex Marital Ther 29 3 (2003) 207-213
66. Tam S.W., Worcel M., and Wyllie M. Yohimbine: a clinical review. Pharmacol Ther 91 3 (2001) 215-243
67. Ernst E., and Pittler M.H. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 159 2 (1998) 433-436
68. Pittler M.H., and Ernst E. Trials have shown yohimbine is effective for erectile dysfunction. BMJ 317 7156 (1998) 478
69. Susset J.G., et al. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 141 6 (1989) 1360-1363
70. Guay A.T., et al. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit?. Int J Impot Res 15 3 (2003) 156-165
71. Kernohan A.F., et al. An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Br J Clin Pharmacol 59 1 (2005) 85-93
72. Lebret T., et al. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol 41 6 (2002) 608-613 [discussion: 613]
73. Johnson S., Iazzetta J., and Dewar C. Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction. J Rheumatol 30 11 (2003) 2503-2505
74. Cohen A.J., and Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 24 2 (1998) 139-143
75. Balon R. Ginkgo biloba for antidepressant-induced sexual dysfunction?. J Sex Marital Ther 25 1 (1999) 1-2
76. Kang B.J., et al. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 17 6 (2002) 279-284
77. Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol 19 8 (2004) 545-548
78. Williamson E.M. Interactions between herbal and conventional medicines. Expert Opin Drug Saf 4 2 (2005) 355-378
79. Izzo A.A., et al. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 98 1 (2005) 1-14
80. Kupiec T., and Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 29 7 (2005) 755-758
81. Ramsay N.A., et al. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 130 5 (2005) 777-780
82. Kim J.Y., et al. Induction of nitric oxide synthase by saponins of heat-processed ginseng. Biosci Biotechnol Biochem 69 5 (2005) 891-895
83. Choi Y.D., Rha K.H., and Choi H.K. In vitro and in vivo experimental effect of Korean red ginseng on erection. J Urol 162 4 (1999) 1508-1511
84. Choi Y.D., Xin Z.C., and Choi H.K. Effect of Korean red ginseng on the rabbit corpus cavernosal smooth muscle. Int J Impot Res 10 1 (1998) 37-43
85. Ryu J.K., et al. Free radical-scavenging activity of Korean red ginseng for erectile dysfunction in non-insulin-dependent diabetes mellitus rats. Urology 65 3 (2005) 611-615
86. Kang K.S., et al. Study on the nitric oxide scavenging effects of ginseng and its compounds. J Agric Food Chem 54 7 (2006) 2558-2562
87. Choi H.K., Seong D.H., and Rha K.H. Clinical efficacy of Korean red ginseng for erectile dysfunction. Int J Impot Res 7 3 (1995) 181-186
88. Hong B., et al. A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol 168 5 (2002) 2070-2073
89. Price A., and Gazewood J. Korean red ginseng effective for treatment of erectile dysfunction. J Fam Pract 52 1 (2003) 20-21
90. Cipolla M.J., et al. Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg 29 6 (1999) 1097-1103
91. Cavallini G., et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 63 4 (2004) 641-646
92. Gentile V., et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 20 9 (2004) 1377-1384
93. Cavallini G., et al. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 66 5 (2005) 1080-1085
94. Eng J., et al. A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2 3 (2003) 212-216
95. Chan J.M., et al. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology 66 6 (2005) 1223-1228
96. Barnes P.M., et al. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 343 (2004) 1-19
97. Carraro J.C., et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29 4 (1996) 231-240 [discussion: 241-2]
98. Boyle P., et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93 6 (2004) 751-756
99. Gerber G.S., et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 58 6 (2001) 960-964 [discussion: 964-5]
100. Beckman T.J., and Mynderse L.A. Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 80 10 (2005) 1356-1362
101. Bent S., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 6 (2006) 557-566
102. Chan J.M., Gann P.H., and Giovannucci E.L. Role of diet in prostate cancer development and progression. J Clin Oncol 23 32 (2005) 8152-8160
103. Anlasik T., et al. Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. Br J Nutr 94 5 (2005) 639-642
104. Sies H., Stahl W., and Sevanian A. Nutritional, dietary and postprandial oxidative stress. J Nutr 135 5 (2005) 969-972
105. Di Mascio P., et al. Carotenoids, tocopherols and thiols as biological singlet molecular oxygen quenchers. Biochem Soc Trans 18 6 (1990) 1054-1056
106. Clinton S.K., et al. cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 5 10 (1996) 823-833
107. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood) 227 10 (2002) 852-859
108. Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 135 8 (2005) 2030S-2031S
109. Giovannucci E., et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87 23 (1995) 1767-1776
110. Giovannucci E., et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94 5 (2002) 391-398
111. Wu K., et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 13 2 (2004) 260-269
112. Lu Q.Y., et al. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev 10 7 (2001) 749-756
113. Vogt T.M., et al. Serum lycopene, other serum carotenoids, and risk of prostate cancer in US Blacks and Whites. Am J Epidemiol 155 11 (2002) 1023-1032
114. Etminan M., Takkouche B., and Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 13 3 (2004) 340-345
115. Cohen J.H., Kristal A.R., and Stanford J.L. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92 1 (2000) 61-68
116. Kolonel L.N., et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 9 8 (2000) 795-804
117. Le Marchand L., et al. Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene. Am J Epidemiol 133 3 (1991) 215-219
118. Hayes R.B., et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8 1 (1999) 25-34
119. Kirsh V.A., et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 1 (2006) 92-98
120. Cook N.R., et al. Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 86 9 (1999) 1783-1792
121. Kirsh V.A., et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98 4 (2006) 245-254
122. Heinonen O.P., et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90 6 (1998) 440-446
123. Gann P.H., et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59 6 (1999) 1225-1230
124. Goodman G.E., et al. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 12 6 (2003) 518-526
125. Eichholzer M., et al. Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: seventeen-year follow-up of the prospective basel study. Prostate 38 3 (1999) 189-198
126. Stahelin H.B., et al. Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year follow-up of the prospective Basel Study. Am J Epidemiol 133 8 (1991) 766-775
127. Vlajinac H.D., et al. Diet and prostate cancer: a case-control study. Eur J Cancer 33 1 (1997) 101-107
128. Tzonou A., et al. Diet and cancer of the prostate: a case-control study in Greece. Int J Cancer 80 5 (1999) 704-708
129. Deneo-Pellegrini H., et al. Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br J Cancer 80 3-4 (1999) 591-597
130. Chan J.M., et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8 10 (1999) 893-899
131. Hartman T.J., et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 7 4 (1998) 335-340
132. Rodriguez C., et al. Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 13 3 (2004) 378-382
133. Hsing A.W., et al. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 82 11 (1990) 941-946
134. Hayes R.B., et al. Serum retinol and prostate cancer. Cancer 62 9 (1988) 2021-2026
135. Hernaandez J., et al. The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. J Urol 174 2 (2005) 519-522
136. Huang H.Y., et al. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 157 4 (2003) 335-344
137. Giovannucci E. Gamma-tocopherol: a new player in prostate cancer prevention?. J Natl Cancer Inst 92 24 (2000) 1966-1967
138. Redman C., et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 18 6 (1997) 1195-1202
139. Griffin A.C. Role of selenium in the chemoprevention of cancer. Adv Cancer Res 29 (1979) 419-442
140. Waters D.J., et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 95 3 (2003) 237-241
141. Chun J.Y., et al. Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther 5 4 (2006) 913-918
142. Lee S.O., et al. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65 8 (2005) 3487-3492
143. Dong Y., et al. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 64 1 (2004) 19-22
144. van den Brandt P.A., et al. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 12 9 (2003) 866-871
145. Ozmen H., et al. Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer. Clin Chem Lab Med 44 2 (2006) 175-179
146. Li H., et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96 9 (2004) 696-703
147. Nomura A.M., et al. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 9 9 (2000) 883-887
148. Yoshizawa K., et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90 16 (1998) 1219-1224
149. Lipsky K., et al. Selenium levels of patients with newly diagnosed prostate cancer compared with control group. Urology 63 5 (2004) 912-916
150. Nyman D.W., et al. Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev 28 1 (2004) 8-16
151. Kumar N.B., et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 59 2 (2004) 141-147
152. Ghadirian P., et al. A case-control study of toenail selenium and cancer of the breast, colon, and prostate. Cancer Detect Prev 24 4 (2000) 305-313
153. Duffield-Lillico A.J., et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91 7 (2003) 608-612
154. Duffield-Lillico A.J., et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11 7 (2002) 630-639
155. Meyer F., et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 116 2 (2005) 182-186
156. Hoenjet K.M., et al. Effect of a nutritional supplement containing vitamin E, selenium, vitamin C and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 47 4 (2005) 433-439 [discussion: 439-40]
157. Klein E.A. Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 1031 (2004) 234-241
158. Lippman S.M., et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97 2 (2005) 94-102
159. Drake E.N. Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med Hypotheses 67 2 (2006) 318-322
160. Platz E.A., et al. Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am J Epidemiol 159 5 (2004) 444-453
161. Barba M., et al. Lifetime total and beverage specific-alcohol intake and prostate cancer risk: a case-control study. Nutr J 3 (2004) 23
162. Sharpe C.R., and Siemiatycki J. Case-control study of alcohol consumption and prostate cancer risk in Montreal, Canada. Cancer Causes Control 12 7 (2001) 589-598
163. Schoonen W.M., et al. Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 113 1 (2005) 133-140
164. Jain M.G., et al. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int J Cancer 78 6 (1998) 707-711
165. Heilbrun L.K., Nomura A., and Stemmermann G.N. Black tea consumption and cancer risk: a prospective study. Br J Cancer 54 4 (1986) 677-683
166. Jian L., et al. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 108 1 (2004) 130-135
167. Sonoda T., et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci 95 3 (2004) 238-242
168. Kinlen L.J., et al. Tea consumption and cancer. Br J Cancer 58 3 (1988) 397-401
169. Bettuzzi S., et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66 2 (2006) 1234-1240
170. Graham H.N. Green tea composition, consumption, and polyphenol chemistry. Prev Med 21 3 (1992) 334-350
171. Sharpe C.R., and Siemiatycki J. Consumption of non-alcoholic beverages and prostate cancer risk. Eur J Cancer Prev 11 5 (2002) 497-501
172. Slattery M.L., and West D.W. Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States). Cancer Causes Control 4 6 (1993) 559-563
173. Ellison L.F. Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur J Cancer Prev 9 2 (2000) 125-130
174. Jatoi A., et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97 6 (2003) 1442-1446
175. Lee A.H., et al. Protective effects of green tea against prostate cancer. Expert Rev Anticancer Ther 6 4 (2006) 507-513
176. Albrecht M., et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 7 3 (2004) 274-283
177. Pantuck A.J., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12 13 (2006) 4018-4026
178. Holzbeierlein J.M., McIntosh J., and Thrasher J.B. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 15 1 (2005) 17-22
179. Lee M.M., et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 12 7 (2003) 665-668
180. Jacobsen B.K., Knutsen S.F., and Fraser G.E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 9 6 (1998) 553-557
181. Hebert J.R., et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 90 21 (1998) 1637-1647
182. Nomura A.M., et al. Cohort study of tofu intake and prostate cancer: no apparent association. Cancer Epidemiol Biomarkers Prev 13 12 (2004) 2277-2279
183. Strom S.S., et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer 33 1 (1999) 20-25
184. Maskarinec G., et al. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men. Eur J Clin Nutr (2006)
185. McCarty M.F. Isoflavones made simple-genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66 6 (2006) 1093-1114
186. Costello L.C., et al. Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). Cancer Causes Control 16 8 (2005) 901-915
187. Moyad M.A. Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer?. Urol Clin North Am 29 1 (2002) 115-124 ix
188. Dhar N.K., et al. Distribution and concentration of zinc in the subcellular fractions of benign hyperplastic and malignant neoplastic human prostate. Exp Mol Pathol 19 2 (1973) 139-142
189. Kristal A.R., et al. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8 10 (1999) 887-892
190. Key T.J., et al. A case-control study of diet and prostate cancer. Br J Cancer 76 5 (1997) 678-687
191. West D.W., et al. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2 2 (1991) 85-94
192. Andersson S.O., et al. Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 68 6 (1996) 716-722
193. Leitzmann M.F., et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95 13 (2003) 1004-1007
194. Kolonel L.N., Yoshizawa C.N., and Hankin J.H. Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 127 5 (1988) 999-1012
195. Sperling H., et al. An extract from the bark of Aspidosperma quebracho blanco binds to human penile alpha-adrenoceptors. J Urol 168 1 (2002) 160-163
196. Choi J., et al. Antinociceptive anti-inflammatory effect of Monotropein isolated from the root of Morinda officinalis. Biol Pharm Bull 28 10 (2005) 1915-1918
197. Di Rocco A., et al. A pilot study of L-methionine for the treatment of AIDS-associated myelopathy. Neurology 51 1 (1998) 266-268
198. James J.S. Frequent urination, leg cramps, leg weakness, erection difficulties: HIV myelopathy amino acid study. AIDS Treat News 344 (2000) 3-4
199. Hitiris N., Barrett J.A., and Brodie M.J. Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy Behav 8 2 (2006) 418-421
200. Hong J.H., et al. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis 9 2 (2006) 147-152
201. Zamble A., et al. Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms. J Cardiovasc Pharmacol 47 4 (2006) 599-608
202. Safarinejad M.R. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 5 4 (2005) 1-11
203. Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 86 4 (2000) 439-442
204. Lopatkin N.A., et al. [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial]. Urologiia 2 (2006) 12, 14-9 [in Russian]
205. Melo E.A., et al. Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz J Urol 28 5 (2002) 418-425
206. Wilt T., et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 1 (2002) CD001044
207. Klippel K.F., Hiltl D.M., and Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80 3 (1997) 427-432
208. Berges R.R., Kassen A., and Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int 85 7 (2000) 842-846
209. MacDonald R., et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 85 7 (2000) 836-841